Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Stoke Therapeutics
Biotech
Stoke's shares up 90% as epilepsy drug cuts convulsive seizures
Investors are stocking up on Stoke, sending the biotech’s shares flying 90% premarket on the back of positive phase 1/2a data for a seizure medicine.
Annalee Armstrong
,
James Waldron
Mar 26, 2024 9:09am
Stoke shares drop 30% as Dravet drug posts high adverse events
Jul 25, 2023 11:49am
Acadia to Stoke up pipeline with $60M CNS research pact
Jan 10, 2022 10:59am
'Leadership is showing': Biotech execs detail being openly LGBTQ
Dec 7, 2021 7:00am
Stoke files for IPO to take drug from preclinical to phase 3
May 24, 2019 9:08am
New discoveries in hematology and epilepsy—News of Note
Dec 3, 2018 12:45pm